The good tolerability profile of enzalutamide, the fact that the administration of steroids is not necessary and the impressive results achieved in prostate cancer, make this drug an ideal candidate to be tested in ovarian granulosa cancer, a tumor that could somehow be considered as "female prostate cancer".
Name: Enzalutamide 40 MG
Description: Number of responses according to RECIST 1.1 criteria
Measure: Overall response rate (ORR) Time: Up to 6 monthsDescription: Stabilization of disease plus the sum of partial and complete responses according to RECIST 1.1 criteria.
Measure: Clinical benefit rate Time: Up to 6 monthsDescription: Number of progression of the disease according to RECIST 1.1 criteria or death of the patient for any cause
Measure: Progression-free survival (PFS) Time: Up to 6 monthsDescription: Number of deaths for any cause.
Measure: Overall survival (OS) Time: Up to 6 monthsDescription: Number of Adverse Events per patient
Measure: Incidence of Treatment-Emergent Adverse Events Time: Up to 6 monthsAllocation: N/A
Single Group Assignment
There is one SNP
Inclusion Criteria: - Patients who have given written informed consent - Women aged 18 years or over - Eastern Cooperative Oncology Group (ECOG) ≤ 1 - Diagnosis of histologically confirmed ovarian granulose carcinoma - Availability of sufficient biopsy material for confirmation of the diagnosis by a centralized pathologist and determination of the mutation FOXL2402C→ G(C134W). --- C134W ---